PROSCAR (finasteride) by Merck & Co. is 5-alpha reductase inhibitors [moa]. First approved in 1992.
Drug data last refreshed 2d ago
PROSCAR (finasteride) is a 5-alpha reductase inhibitor oral tablet approved in 1992 for benign prostatic hyperplasia, androgenetic alopecia, and other androgen-dependent conditions. It works by inhibiting the conversion of testosterone to dihydrotestosterone, reducing prostate volume and slowing hair loss. The drug has an expanded label addressing prostate cancer, sexual dysfunction, hematuria, and muscle atrophy indications.
As LOE approaches, brand team focus shifts from growth to lifecycle extension and generic transition strategies; smaller commercial teams manage declining revenue.
5-alpha Reductase Inhibitors
5-alpha Reductase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy
On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)
Worked on PROSCAR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROSCAR brand team roles are largely stable-state, focused on managed decline rather than growth initiatives. Career development is constrained by product maturity, making this a consolidation role better suited for experienced managers transitioning to post-LOE strategy rather than early-career launch specialists.